Please login to the form below

Not currently logged in
Email:
Password:

Pfizer's Robert Clark to move to Novo Nordisk

Will join firm’s US operations as vice president of regulatory affairs

Novo Nordisk has appointed Robert Clark as vice president of regulatory affairs in a role that will see him lead the Danish pharma company's US regulatory team.

He will also be tasked with maintaining “relationships with key individuals and agencies outside of Novo Nordisk that play a specific role in the US Food and Drug Administration's (FDA) review and approval process”, Novo said.

Clark will join the company on May 14 from Pfizer, where he was US regulatory strategy head, leading or supporting approvals of new cardiovascular, endocrine, women's health and anti-infective medicines.

"Bob is bringing 27 years of experience and knowledge of the global and US regulatory environment, and it's that know-how we require for an increasingly complex pharmaceutical marketplace," said Anne Philips, corporate vice president of clinical development, medical and regulatory affairs at Novo Nordisk.

"Novo Nordisk has one of the most promising diabetes pipelines in the industry, and having a respected leader known to regulatory authorities will help us achieve our ongoing mission to bring new therapies to patients."

9th May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics